XML 111 R77.htm IDEA: XBRL DOCUMENT
v3.5.0.2

Collaborative and Other Relationships Collaborative and Other Relationships - Collaborations (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended |  |
--- | --- | --- | --- | ---
Jun. 30, 2016 | Jun. 30, 2015 | Jun. 30, 2016 | Jun. 30, 2015 | Dec. 31, 2015 | Jan. 31, 2007
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Research and development | $ 473.1 | $ 490.7 | $ 910.4 | $ 951.3 |  |
Investments and other assets | 1,153.0 |  | $ 1,153.0 |  | $ 1,107.6 |
Sobi rate to Biogen on net sales in the Sobi Territory |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Reimbursement under the amended agreement method |  |  | Royalty |  |  |
Base rate after first commercial sale |  |  | 12.00% |  |  |
Rate during the reimbursement period |  |  | Base Rate plus 5% |  |  |
Biogen rate to Sobi on net sales in the Biogen North America Territory |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Reimbursement under the amended agreement method |  |  | Royalty |  |  |
Rate during the reimbursement period |  |  | Base Rate less 5% |  |  |
Biogen rate to Sobi on net sales in the Biogen North America Territory | Sobi Territory |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Base rate after first commercial sale |  |  | 12.00% |  |  |
Biogen rate to Sobi on net sales in the Biogen Direct Territory |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Reimbursement under the amended agreement method |  |  | Royalty |  |  |
Rate during the reimbursement period |  |  | Base Rate less 5% |  |  |
Biogen rate to Sobi on net sales in the Biogen Direct Territory | Sobi Territory |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Base rate after first commercial sale |  |  | 17.00% |  |  |
Biogen rate to Sobi on net revenue from the Biogen Distributor Territory |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Reimbursement under the amended agreement method |  |  | Net Revenue Share |  |  |
Rate during the reimbursement period |  |  | Base Rate less 15% |  |  |
Biogen rate to Sobi on net revenue from the Biogen Distributor Territory | Sobi Territory |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Base rate after first commercial sale |  |  | 50.00% |  |  |
Biogen Hemophilia |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Percentage of stock acquired |  |  |  |  |  | 100.00%
University of Pennsylvania |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Research and development | 20.0 |  |  |  |  |
Investments and other assets | 15.0 |  | $ 15.0 |  |  |
Future research and development commitment | 47.5 |  | 47.5 |  |  |
Potential future milestone payments | $ 2,000.0 |  | $ 2,000.0 |  |  |
Swedish Orphan Biovitrum |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Reimbursement recognition period |  |  | 10 years |  |  |
Reimbursement cost achieving period |  |  | 6 years |  |  |
Time period for paying remaining balance due |  |  | 90 days |  |  |
Swedish Orphan Biovitrum | ELOCTATE |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Research and development |  |  | $ 157.0 |  |  |
Swedish Orphan Biovitrum | ALPROLIX |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Research and development |  |  | $ 130.0 |  |  |

X
- Definition Base rate after first commercial sale. + References No definition available. + Details
Name: | biib_BaseRateAfterFirstCommercialSale
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Future research and development commitment + References No definition available. + Details
Name: | biib_Futureresearchanddevelopmentcommitment
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Potential future milestone payments commitment to third party approximately. + References No definition available. + Details
Name: | biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Rate during the reimbursement period. + References No definition available. + Details
Name: | biib_RateDuringReimbursementPeriod
Namespace Prefix: | biib_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Reimbursement cost achieving period. + References No definition available. + Details
Name: | biib_ReimbursementCostAchievingPeriod
Namespace Prefix: | biib_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Reimbursement, under the amended agreement, method. + References No definition available. + Details
Name: | biib_ReimbursementUnderAmendedAgreementMethod
Namespace Prefix: | biib_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Reimbursement recognition period + References No definition available. + Details
Name: | biib_Reimbursementrecognitionperiod
Namespace Prefix: | biib_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Time period for paying remaining balance due. + References No definition available. + Details
Name: | biib_TimePeriodForPayingRemainingBalanceDue
Namespace Prefix: | biib_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of voting equity interests acquired at the acquisition date in the business combination. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1392-128463 + Details
Name: | us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of noncurrent assets classified as other. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.17) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_OtherAssetsNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Research and Development -URI http://asc.fasb.org/extlink&oid=6523717 + Details
Name: | us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis=biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis=biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=biib_SobiTerritoryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis=biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis=biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=biib_BiogenIdecHemophiliaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=biib_UniversityofPennsylvaniaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=biib_SwedishOrphanBiovitrumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=biib_ELOCTATEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=biib_ALPROLIXMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |